FDA less trusted than pharma, says poll

Share this article:
A poll suggests that, amid drug safety worries, the FDA is less trusted than the drug industry.
A recent Wall Street Journal Online/Harris Interactive Health Care Poll found that six in 10 adults gave the agency a negative rating on the function they rated its most important: ensuring the safety and efficacy of prescription drugs.

Eighty percent of respondents said they were very or somewhat concerned about the agency's ability to “make independent decisions that will ensure that patients have access to safe and effective medicines.” Asked how good a job the FDA is doing on that front, 58% said “fair” or “poor,” while just 36% said “good” or “excellent,” a reversal from ratings two years ago.

By comparison, only 36% of those surveyed in a recent Harris Interactive industry reputation poll said pharmaceutical firms were doing a bad job of serving consumers, with 61% saying they were doing a good job.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...